NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) have received an average recommendation of “Moderate Buy” from the five research firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $8.50.

Separately, Weiss Ratings downgraded shares of NeuroSense Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 30th.

Insider Activity

In other NeuroSense Therapeutics news, CEO Alon Ben-Noon bought 250,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The stock was purchased at an average price of $0.80 per share, with a total value of $200,000.00. Following the transaction, the chief executive officer owned 4,534,233 shares in the company, valued at $3,627,386.40. This trade represents a 5.84% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Or Eisenberg acquired 250,000 shares of the business’s stock in a transaction on Tuesday, June 16th. The stock was bought at an average cost of $0.80 per share, for a total transaction of $200,000.00. Following the completion of the transaction, the chief financial officer directly owned 1,504,050 shares of the company’s stock, valued at $1,203,240. This trade represents a 19.94% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 27.40% of the company’s stock.

Institutional Investors Weigh In On NeuroSense Therapeutics

Large investors have recently added to or reduced their stakes in the company. Two Sigma Investments LP purchased a new stake in NeuroSense Therapeutics during the 3rd quarter worth $26,000. Jane Street Group LLC acquired a new stake in shares of NeuroSense Therapeutics during the second quarter valued at about $54,000. Yorkville Advisors Global LP acquired a new stake in shares of NeuroSense Therapeutics during the fourth quarter valued at about $77,000. Finally, Squarepoint Ops LLC increased its position in shares of NeuroSense Therapeutics by 91.0% during the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after acquiring an additional 45,450 shares during the last quarter. 1.04% of the stock is owned by institutional investors and hedge funds.

NeuroSense Therapeutics Stock Performance

Shares of NRSN stock opened at $0.50 on Friday. The stock has a fifty day moving average price of $0.69 and a 200 day moving average price of $0.79. The stock has a market cap of $19.00 million, a PE ratio of -0.93 and a beta of 1.62. NeuroSense Therapeutics has a 1 year low of $0.39 and a 1 year high of $1.98.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.